Abbott India Ltd Q1 FY23 Share Price & Earnings Call Analysis

24out of 100

Momentum score · price trend

24 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,905 stocks
Last 12 months−16.9%43%
Last 6 months−0.6%54%
Last 3 months−10.6%44%

The price is 28.5% below its all-time high of ₹35,008.75 (27 Jun 2025). Stocks more than 20% below their peak have their score halved, so 48 became 24.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,905 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Abbott India Ltd: 0.4 × 43 + 0.4 × 54 + 0.2 × 44 = 48, halved to 24 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 23 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Financials of Abbott India Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Abbott India Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +1,3431,4791,4941,4371,4391,5581,6331,6141,6051,7381,7571,7241,710
Expenses +1,0631,1241,1131,0491,1091,1671,1941,1781,1761,2931,2551,2611,229
Operating Profit280355381388330391439436429446502463481
OPM %21%24%25%27%23%25%27%27%27%26%29%27%28%
Other Income +50565656816760727673707076
Interest4333332246856
Depreciation17171818181818181819191919
Profit before tax308390415422390437479488483493546509531
Tax %25%26%25%26%26%25%25%26%24%26%24%26%26%
Net Profit +231290313311287328359361367366415376395
EPS in Rs108.91136.59147.27146.35135.09154.36168.76169.78172.73172.18195.43176.93185.86

Financials of Abbott India Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +2,2892,6142,9033,2983,6794,0934,3104,9195,3495,8496,4096,929
Expenses +1,9772,2502,5052,7743,0743,3363,3883,8324,1434,3964,7145,037
Operating Profit3123653985256057579221,0881,2061,4531,6951,892
OPM %14%14%14%16%16%18%21%22%23%25%26%27%
Other Income +4850571171131148177154248275288
Interest032429181916121125
Depreciation151416161760586670717276
Profit before tax3443984366216998039261,0801,2741,6181,8872,079
Tax %34%36%37%35%36%26%25%26%25%26%25%25%
Net Profit +2292552774014505936917999491,2011,4141,552
EPS in Rs107.75120.12130.19188.82211.93279.04325.04375.87446.80565.30665.64730.39
Dividend Payout %29%29%31%29%31%90%85%73%73%73%71%65%

Financials of Abbott India Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital212121212121212121212121
Reserves9161,1741,3661,6721,9872,4102,5812,7993,1673,6784,2124,753
Borrowings +0000017515315211383197172
Other Liabilities +4364216797239329401,0861,2531,2541,4111,4871,556
Total Liabilities1,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9176,502
Fixed Assets +9610811081105270251271237225336331
CWIP43621211410186
Investments000000000000
Other Assets +1,2741,5051,9502,3332,8353,2753,5893,9524,3154,9585,5636,165
Total Assets1,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9176,502

Financials of Abbott India Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +2152493071534996267279488931,2131,0121,319
Cash from Investing Activity +-187-77-155-215-257-401-72-396-148-416182-371
Cash from Financing Activity +-58-80-90-102-143-217-582-637-639-745-925-1,066
Net Cash Flow-309162-16599873-8610752269-118
Free Cash Flow1992262871805046117049048601,1659601,307
CFO/OP106%109%117%68%125%113%104%114%102%111%86%98%

Financials of Abbott India Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days212022292728212122202219
Inventory Days10791107112106831109480709294
Days Payable545610192116104116122109114110109
Cash Conversion Cycle7454284917814-6-8-2433
Working Capital Days3032216322104-7-8-14972
ROCE %40%38%34%41%37%35%35%38%41%46%46%45%

Continue your research

What Abbott India Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sat Kartar Life Ltd (Q2 FY27)

    113.87 crores (Page 8) . Key results statement takeaways from Sat Kartar Life Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Torrent Pharmaceuticals Ltd (Q2 FY27)

    4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect

  • Sakar Healthcare Ltd (Q2 FY27)

    2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se

  • Dr Reddys Laboratories Ltd (Q2 FY27)

    Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd